MD State Legislature Hearings
Check back for updates on the next round of supported bill hearings.
Maryland 2025 Legislative Session
Supported Legislation & Legislation of Interest
SB 303 / HB 321
​SB 303 / HB 321 – Pharmacy Benefits Managers - Definition of Purchaser and Alteration of Application of Law
​
These bills will further expand the Rutledge decision to cover more aspects of ERISA PBMs under the Insurance Code. As you will recall, this bill has advanced in the House of Delegates previously, but has stalled in the Senate. The bill makes the following provisions of the Insurance Article apply to all PBMs:
-
information on and sales of prescription drugs (§ 15-1611);
-
choice of pharmacy by a beneficiary (§ 15-1611.1);
-
reimbursement for a pharmaceutical product or pharmacist service (§ 15-1612);
-
requirements before entering into a contract (§ 15-1623);
-
rebate sharing contract requirements (§ 15-1624);
-
audits by PBMs (§ 15-1629); and
-
internal review process requirements (§ 15-1630) ​
SB 438
SB 438 – Pharmacy Benefits Administration - Maryland Medical Assistance Program and Pharmacy Benefits Managers
​
This bill requires Medicaid to establish minimum reimbursement levels for drug products with a generic equivalent that are at least equal to the National Average Drug Acquisition Cost (NADAC) of the generic product plus the fee-for-service (FFS) professional dispensing fee. If a prescriber directs a specific brand name drug, reimbursement must be based on the NADAC of the brand name product plus the FFS professional dispensing fee. These requirements do not apply to (1) a pharmacy owned by, or under the same corporate affiliation as, a pharmacy benefits manager (PBM) or (2) a mail order pharmacy. A PBM that contracts with a pharmacy on behalf of a Medicaid managed care organization (MCO) must reimburse the pharmacy in an amount that is at least equal to the NADAC plus the FFS professional dispensing fee.​